Beyond the Symptom: Pharmacy’s Functional Medicine Revolution

Beyond the Symptom: Pharmacy’s Functional Medicine Revolution

This SIG meeting will explore the foundational principles of functional medicine and how pharmacists can look beyond symptom management to better understand the root causes of health concerns. Discussion will include the Functional Medicine Matrix, advanced specialty testing, and lifestyle and nutritional approaches to personalized patient care. Participants will explore how functional medicine principles can be incorporated into pharmacy practice, including opportunities for personalized consultations. The meeting will conclude with a discussion of three patient cases evaluated through a functional medicine lens.

Renee Prescott, PharmD, AFMC | F.A.M.E. Health and Wellness

Bio: Dr. Renee Prescott is a functional medicine specialist, certified health coach, and pharmacist with over 20 years’ experience in the personalized medicine industry. She has been a speaker and facilitator at 100s of conferences, as well as written articles and textbook chapters in the pharmaceutical space. Renee graduated from the University of Houston College of Pharmacy in 2002 and received her Applied Functional Medicine Certification from the School of Applied Functional Medicine in March of 2024. In addition to owning F.A.M.E. Health and Wellness, Renee spends her time as the Senior Director of Education at PCCA where she creates and executes continuing education events.

Explore the foundations of functional medicine and how pharmacists can look beyond symptoms to identify root causes of health concerns. This SIG meeting will cover the Functional Medicine Matrix, advanced specialty testing, lifestyle and nutritional approaches, and personalized patient consultations. The discussion will conclude with three patient cases demonstrating how functional medicine principles can be applied in pharmacy practice.

This meeting will not offer CE.

Missed the meeting – CLICK HERE, to view

COMPOUNDING SIG: To 503B or Not to 503B: That is the Question?

Linda Hicks2026-10-07T16:23:22-05:00September 15th, 2026|Categories: 503B, Business, Compliance, compounding, Compounding SIG, FDA, Outsourcing Facility, Pharmacy Law, Pharmacy Practice, Regulatory Issues|Tags: 503A vs 503B, 503B, 503B compounding, 503B outsourcing facility, ACA, American College of Apothecaries, compounding pharmacy, compounding pharmacy business, compounding regulations, Compounding SIG, controlled substances, DEA, FDA, FDA regulations, outsourcing facility, pharmaceutical compounding, pharmacy business, pharmacy compliance, pharmacy law, pharmacy operations, pharmacy regulations, regulatory compliance, sterile compounding|

DID YOU MISS THE MEETING?

LISTEN NOW

Should your pharmacy consider 503B outsourcing? What are the opportunities, costs, and regulatory considerations?

Join us for a discussion of the 503B outsourcing facility model and how it differs from traditional pharmacy compounding. We’ll explore the current 503B market, capital and operational requirements, regulatory differences, and important considerations for pharmacies evaluating whether 503B may be right for their business.

The discussion will also include a separate look at controlled substances and the additional regulatory requirements and considerations that apply.

Whether you are considering entering the 503B space, partnering with a 503B facility, or simply want to better understand the differences, this SIG will provide valuable insight to help you make informed decisions.

Join us for this informative and timely discussion on one of the important questions facing compounding pharmacies today.

Erik Tosh, RPh, FACA, brings more than 40 years of pharmacy experience and nearly five decades of experience in healthcare, with a career spanning hospital pharmacy, independent community pharmacy, pharmaceutical compounding, and industry leadership. His extensive compounding experience includes serving as Director of Operations for a large sterile compounding facility that later became registered as a 503B outsourcing facility. In that role, he oversaw operations that included production, regulatory and compliance activities, purchasing, shipping, and the preparation of high-risk compounded medications for hospitals across the United States.

Tosh later served as Vice President of Compounding Support Services at Letco Medical, where he led compounding support initiatives, developed continuing education programs, provided technical training, and worked closely with professional pharmacy organizations. He retired in 2021.

In addition to his industry experience, Tosh has served as adjunct faculty at Western University College of Pharmacy and has presented ACPE-accredited education on pharmaceutical compounding. He is a past President and Chairman of the International Academy of Compounding Pharmacists and has contributed to professional publications including Remington: The Science and Practice of Pharmacy and the International Journal of Pharmaceutical Compounding.

Considering the move to 503B? Join us for a discussion of what it takes to start or transition to a 503B Outsourcing Facility. We’ll begin with an overview of the key considerations involved, then open the conversation for attendees to ask questions, share experiences, and exchange perspectives.

This meeting will not offer CE.

LISTEN NOW

Missed the meeting – CLICK HERE, to view

address

navigation

affiliates

connect

refer a colleague